Two patents currently held, every record listed here

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2032. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Mar 2032

Next term end

Patent families

When these terms end

Each bar runs from grant to computed term end. 2015 to 2040.

US 9,187,418 Method for the Preparation of (3S, 3S') 4,4'-Disulfanediylbis (3-Aminobutane 1-Sulfonic Acid) Mar 5, 2032

US 11,345,658 Compounds and Compositions Comprising the Same for Treating Hypertension or Heart Failure Mar 11, 2040

20202025203020352040

Every computed term in this portfolio is shown above.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Only 2 of the currently held patents qualify as notable.

Notable

Method for the Preparation of (3S, 3S') 4,4'-Disulfanediylbis (3-Aminobutane 1-Sulfonic Acid) US 9,187,418

Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2032.

Ends Mar 2032 · High confidence Also notable

Compounds and Compositions Comprising the Same for Treating Hypertension or Heart Failure US 11,345,658

Granted 2022. Computed term ends 2040.

Ends Mar 2040 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due May 17, 2027
The maintenance fee for Method for the Preparation of (3S, 3S') 4,4'-Disulfanediylbis (3-Aminobutane 1-Sulfonic Acid) (US 9,187,418) comes due May 17, 2027. Unpaid by Nov 17, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Compounds and Compositions Comprising the Same for Treating Hypertension or Heart Failure	1 in force	to Mar 2040
Method for the Preparation of (3S, 3S') 4,4'-Disulfanediylbis (3-Aminobutane 1-Sulfonic Acid)	1 in force	to Mar 2032

Patents held now

Soonest term end first.

Showing 1 to 2 of 2

Patent	Title	Status	Expires	Confidence
US 9,187,418	Method for the Preparation of (3S, 3S') 4,4'-Disulfanediylbis (3-Aminobutane 1-Sulfonic Acid) In force Term ends Mar 5, 2032 · High confidence	In force	Term ends Mar 5, 2032	High confidence
US 11,345,658	Compounds and Compositions Comprising the Same for Treating Hypertension or Heart Failure held by Quantum Genomics, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique and College de France In force Term ends Mar 11, 2040 · High confidence	In force	Term ends Mar 11, 2040	High confidence

Also on record, not counted in the 2: 2 patents ended · 2 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Quantum Genomics